Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance
NCT03311958
·
clinicaltrials.gov ↗
EARLY_PHASE1
Phase
COMPLETED
Status
15
Enrollment
OTHER
Sponsor class
Conditions
Diffuse Large B Cell Lymphoma
Interventions
DRUG:
Nivolumab, IV, 240 mg
Sponsor
Fox Chase Cancer Center